Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of 18F Labeled Probe Targeting Fibroblast Activation Protein Inhibitor and Integrin avβ3 (FAPI-RGD) in Breast Tumors

NCT05976620 is registered in ClinicalTrials.gov with Sichuan Provincial People's Hospital as lead sponsor.

NCT NCT05976620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05976620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of 18F Labeled Probe Targeting Fibroblast Activation Protein Inhibitor and Integrin avβ3 (FAPI-RGD) in Breast Tumors
Lead sponsor
Sichuan Provincial People's Hospital
Phase
Observational
Overall status
Completed
Start date
June 20, 2023
Completion date
February 20, 2024
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast tumors